
QNCX Stock Forecast & Price Target
QNCX Analyst Ratings
Bulls say
Quince Therapeutics Inc is positioned positively due to its strategic agreements with the FDA, particularly the special protocol assessment (SPA) that supports the approval process for its lead program, eDSP, pending success in the Phase 3 NEAT trial. The company’s long-term safety data for eDSP in pediatric patients with Ataxia-Telangiectasia is notable, demonstrating a strong tolerability profile without significant corticosteroid-related toxicities, which enhances the credibility of the program as it advances. Overall, the promising results from previous trials and the company’s innovative drug delivery platform contribute to a favorable valuation outlook and reduced risk profile, positioning Quince Therapeutics for potential growth within the biopharmaceutical sector.
Bears say
Quince Therapeutics has faced a significant setback following the dismal results from its pivotal Phase 3 NEAT clinical trial for eDSP in Ataxia-Telangiectasia, which failed to meet both primary and secondary endpoints, leading to a substantial downgrade in market outlook. The management's decision to halt development of eDSP notably restricts the company's pipeline options, indicating a shift in focus from clinical development to financial sustainability. Furthermore, the company’s shares plummeted 92% after the trial results, underscoring the market's negative sentiment, while the absence of commercialization history and projected ongoing net losses exacerbate the financial risks associated with the stock.
This aggregate rating is based on analysts' research of Quince Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
QNCX Analyst Forecast & Price Prediction
Start investing in QNCX
Order type
Buy in
Order amount
Est. shares
0 shares